Current Report · Items 5.02 · 8-K

Johnson & Johnson

JNJNYSEEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Filed Jun 10, 2025Accepted Jun 10, 2025, 5:06 PM EDTCIK 200406Accession 0000200406-25-000152

Company context

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/.

Current securities

JNJNYSE · EQUITY · Current

Recent company filings

Disclosure sections

Items 5.02

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On June 10, 2025, Johnson & Johnson (the “Company” or “Johnson & Johnson”) announced that Daniel Pinto was elected to the Board of Directors effective July 1, 2025. Mr. Pinto will serve on the Audit Committee and the Compensation & Benefits Committee. As a non-employee director of the Company, Mr. Pinto will receive compensation as described in the “Director Compensation” section of the Company’s 2025 Proxy Statement. Mr. Pinto currently serves as the President of JPMorganChase and will serve as Vice Chairman of the firm from July 1, 2025 through his retirement at the end of 2026. He previously served as Chief Operating Officer, among other roles, during his tenure at the firm. JPMorganChase provides a variety of banking services to the Company. During fiscal year 2024, Johnson & Johnson paid JPMorganChase approximately $39.2 million for banking services including fees associated with routine banking services, supplier financing, short-term debt instruments and M&A advisory services. The Company’s press release announcing the appointment is attached to this Report as Exhibit 99.1.

Filed exhibits (1)

EX-99.1 (by filename) ex991-pressrelease.htm

EX-99 2 ex991-pressrelease.htm EX-99 Document Exhibit 99.1 Media contact: Investor contact: media-relations@its.jnj.com investor-relations@its.jnj.com FOR IMMEDIATE RELEASE Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors New Brunswick, New Jersey (June 10, 2025) - Johnson & Johnson (NYSE: JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. “We are thrilled to have Daniel join Johnson & Johnson’s Board of Directors,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel’s unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare innovation for patients.” “I’ve long admired Johnson & Johnson’s continued investment in scientific innovation and its commitment to improving health outcomes for patients facing the most challenging diseases,” said Daniel Pinto. “It’s an honor to jo…

Open exhibit ↗

Get the free weekly BCS email.